OncoMatch/Clinical Trials/NCT04278287

Chemoradiotherapy in Unresectable Esophageal Cancer

Is NCT04278287 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies multiple treatments including Albumin-Bound Paclitaxel and Cisplatin for esophageal cancer.

Phase 1/2RecruitingCancer Institute and Hospital, Chinese Academy of Medical SciencesNCT04278287Data as of May 2026

Treatment: Albumin-Bound Paclitaxel · Cisplatin — This phase I/II clinical study is designed to evaluate the 1 year local tumor control rate of chemoradiotherapy using albumin-bound paclitaxel and cisplatin in unresectable esophageal squamous cell carcinomas based on Nutritional Risk Screening NRS2002.

Check if I qualify

Extracted eligibility criteria

Cancer type

Esophageal Carcinoma

Tumor Agnostic

Disease stage

Required: Stage T3N1M0-1B, T4N0-1M0-1B

Performance status

ECOG 0–1(Restricted strenuous activity)

Lab requirements

Blood counts

hemoglobin >= 100g/l; leukocytes >= 4,000 g/l; neutrophil >= 2,000 g/l; platelets >= 100,000/mm3

Kidney function

creatinine <= 1.5x uln or ccr >= 60 ml/min

Liver function

ast/alt <= 2.5x uln; total bilirubin <= 1.5x uln

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify